ArticleFrontiers in medical technology2025
Optimization of bacteriocin production by
Article in Frontiers in medical technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lactic acid bacterial strains isolated fromFrontiers in microbiology · 2026Article
- Neuroprotective role ofFrontiers in nutrition · 2026Article
- Bactericidal and cell membrane disruption potential of protein extract from buttermilk-derived probioticFrontiers in microbiology · 2026Article
- Mitigating gut dysbiosis induced by biofilm-forming pathogens: therapeutic potential of LAB-derived bacteriocins.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins are ribosomally produced, proteinaceous antimicrobial biomolecules with versatile functions and are considered potential next-generation therapeutics. They are secreted by a few groups of lactic acid bacteria (LAB) that possess the ability to combat spoilage and foodborne pathogens. Given these properties, bacteriocins have generated significant interest for their potential use as natural food preservatives. This study aimed to isolate and characterize bacteriocin-producing LAB with potent antimicrobial properties and evaluate their potential use as natural food preservatives and alternative therapeutics. A total of 47 morphologically distinct LAB isolates were screened for antibacterial activity against foodborne pathogens. The isolate exhibiting the strongest antimicrobial activity, designated CW40, was selected for further study. The bacteriocin was purified from the culture supernatant using gel filtration chromatography. The isolate was identified by 16S rDNA sequencing, and optimal conditions for bacteriocin production were determined. The molecular weight of the bacteriocin was estimated, and its antimicrobial spectrum, enzyme sensitivity, bile salt tolerance, and antibiotic resistance profile were assessed. Isolate CW40 produced 8 kDa (MW) of bacteriocin from the purified supernatant of its grown culture and was identified as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.